IP Verse

Hbv Antisense Inhibitors

EP2512491

GLAXO GROUP LIMITED
Application Number
EP10824199A
Filing Date
Oct 15, 2010
Status
Revoked
Apr 17, 2020
Grant Date
Oct 11, 2017
External Links
Slate, Register

Biblio Summary

The patent EP2512491B1 was granted on Oct 11, 2017 by Glaxo Group Limited The patent is currently Revoked.

Oppositions Filed by other Companies on the Patent

The table below shows 1 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

ROCHE INNOVATION CENTER COPENHAGEN A/SJul 10, 2018 N.A.

More Opposed Patents of Glaxo Group Limited

The table below shows the patents of Glaxo Group Limited that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3578169Pharmaceutical Formulations Comprising 4-{(1 R)-2-[(6-{2-[(2,6-Dichlorobenzyl)Oxy]Ethoxy}Hexyl)Amino]-1-Hydroxyethyl}-2-(Hydroxymethyl)PhenolJun 26, 20241
EP1907037Medicament DispenserSep 7, 20221
EP2005372Counter For Use With A Medicament DispenserMay 18, 20221

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.

  • Date

    Description

  • Get instant alerts for new documents